Although CCCP is an experimental agent with no therapeutic value clinically, further studies are necessary to decipher the mechanisms underlying the CST-CCCP synergy to inform the development of adjuvants that could be therapeutically effective in CST-resistant infections.īacterial resistance to last-resort antibiotics viz., carbapenems (CAR), colistin (CST), and tigecycline (TGC), continues to pose a major clinical challenge to infection treatment and management throughout the world ( Osei Sekyere, 2016 Osei Sekyere et al., 2016b). We concluded that CCCP reverse CST resistance in CST-resistant Enterobacteriaceae. Eight isolates tested positive for the MEM-CCCP disc synergy test. Addition of CCCP reversed resistance to CST, TGC, IMP, and MEM in 44, 3, 0, and 0 isolates respectively CST had the highest mean minimum inhibitory concentration (MIC) fold change (193.12 p < 0.0001) post CCCP compared to that of MEM (1.70), IMP (1.49) and TGC (1.16). Results and conclusions: Susceptibility to MEM, imipenem (IMP), CST, and TGC was found in only 2, 0, 17, and 9 isolates respectively. oxytoca/michiganensis ( n = 2) with known carbapenem resistance mechanisms and undescribed CST and TGC resistance mechanisms were subjected to broth microdilution and meropenem (MEM) disc synergy test in the presence and absence of carbonyl cyanide m-chlorophenylhydrazine (CCCP), a H + conductor (protonophore). ( n = 15), Serratia marcescens ( n = 12), Citrobacter freundii ( n = 8), Escherichia coli ( n = 2), and K. Methods: Sixty-three clinical Enterobacteriaceae isolates comprising of Klebsiella pneumoniae ( n = 24), Enterobacter spp. Hence, the quest to find other agents that will synergistically restore the efficacy of these antibiotics have increased. However, resistance to these reserve antibiotics are increasingly being reported worldwide. 3Biomedical Resource Unit, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africaīackground: Carbapenems (CAR), colistin (CST), and tigecycline (TGC) alone or in combination therapy has become the last-resort antibiotics for treating infections caused by multidrug resistant (MDR) bacteria.2Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
1Division of Microbiology, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
0 kommentar(er)
